[18F]UCB-H 突触囊泡蛋白 2A PET 检测癫痫局灶性病变
该研究在29例耐药性单侧局灶性癫痫患者中比较了动态[18F]UCB-H SV2A PET与静态[18F]FDG PET,发现SV2A结合药物可显著降低晚期[18F]UCB-H结合,双时相SV2A PET提供互补的灌注样与突触信息,并与[18F]FDG PET空间对应但突触信号改变更局限。
要点
- SV2A结合药物使晚期[18F]UCB-H结合降低达75%,示踪剂靶点特异性高。
- 早期(0-10分钟)和晚期(30-60分钟)SV2A PET病灶严重程度均与[18F]FDG摄取相关。
- 仅早期SV2A PET病灶体积与[18F]FDG病灶体积相关,晚期SV2A PET勾勒突触异常更清晰。
核心结论
- 双时相[18F]UCB-H PET在局灶性癫痫中提供互补的灌注样和突触信息,与[18F]FDG PET空间对应且突触信号改变更局限。
研究设计与样本
- 29例耐药性单侧局灶性癫痫患者接受动态[18F]UCB-H PET(0-60分钟)和静态[18F]FDG PET(30-50分钟)成像。
- 8例患者接受SV2A结合药物左乙拉西坦或布瓦西坦治疗。
- 从35帧提取[18F]UCB-H时间-活度曲线,计算各帧与[18F]FDG摄取的Pearson相关系数以确定最佳成像窗口。
- 计算致痫半球与对侧健康半球体素百分比差异以确定病灶严重程度和体积,并评估高斯平滑核在病灶检测中最小化背景噪声同时保留对比度。
主要发现
- SV2A结合药物治疗使晚期[18F]UCB-H结合较未治疗者降低达75%,示踪剂靶点特异性高。
- 对侧未受影响半球逐帧相关分析显示[18F]UCB-H与[18F]FDG摄取在注射后0-10分钟和30-60分钟区间显著相关,分别选为早期和晚期分析窗口。
- 致痫灶内SV2A PET病灶严重程度与[18F]FDG摄取在早期(r=0.61,P=0.0042)和晚期(r=0.63,P=0.0027)均相关。
- 仅早期SV2A PET病灶体积与[18F]FDG病灶体积相关(r=0.70,P=0.0004),晚期SV2A PET体积不相关。
- [18F]FDG和早期[18F]UCB-H PET视觉显示致痫区周围广泛低代谢和低灌注区域,而晚期[18F]UCB-H PET对突触异常给出更清晰、高对比度的勾勒。
临床怎么用
- 双时相[18F]UCB-H SV2A PET可作为局灶性癫痫的补充成像手段,与[18F]FDG PET联合评估致痫区。
- 晚期[18F]UCB-H PET可能有助于更局限地勾勒突触异常区域。
- 接受SV2A结合药物治疗的患者需考虑药物对晚期[18F]UCB-H结合的降低效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Synaptic vesicle protein 2A (SV2A) is a universal marker of synaptic density. Recent advances in SV2A-targeted radiotracers have opened new windows into synaptic imaging. In focal epilepsy, synaptic dysfunction is a central pathologic feature. Unlike [18F]FDG PET, which reflects neuronal metabolism only indirectly, SV2A PET allows for direct quantification of synaptic density. We therefore evaluated [18F]UCB-H SV2A PET in comparison to [18F]FDG PET in patients with pharmacoresistant, unilateral focal epilepsy, aiming to assess its complementary value to established metabolic imaging. Methods: In total, 29 patients with unilateral focal epilepsy underwent both dynamic [18F]UCB-H PET (0-60 min) and static [18F]FDG PET (30-50 min) imaging. Eight patients were treated with the SV2A-binding medications levetiracetam or brivaracetam. [18F]UCB-H PET time-activity curves were extracted from 35 frames across cortical and subcortical regions, and Pearson correlation coefficients with [18F]FDG uptake were calculated for each frame to identify the most suitable imaging windows. Voxelwise percentage differences between epileptogenic and contralateral healthy hemispheres were computed to determine lesion severity and volume. Finally, we evaluated gaussian smoothing kernels for minimizing background noise while preserving contrast during lesion detection. Results: Treatment with SV2A-binding medications reduced late-phase [18F]UCB-H binding up to 75% compared with untreated individuals, demonstrating high target specificity. Framewise correlation analysis in unaffected contralateral hemispheres revealed significant associations between [18F]UCB-H and [18F]FDG uptake within the 0-10-min and 30-60-min postinjection intervals. These time windows were therefore selected for early- and late-phase analyses, respectively. Within epileptogenic foci, SV2A PET lesion severity correlated with [18F]FDG uptake for both early-phase (r = 0.61, P = 0.0042) and late-phase (r = 0.63, P = 0.0027) imaging. However, only early-phase SV2A PET lesion volume correlated with [18F]FDG lesion volume (r = 0.70, P = 0.0004), whereas late-phase SV2A PET volume did not. In line, [18F]FDG and early-phase [18F]UCB-H PET visually showed broad hypometabolic and hypoperfused areas around the epileptogenic zone, whereas late-phase [18F]UCB-H PET yielded sharper, high-contrast delineation of synaptic abnormalities. Conclusion: Dual-phase [18F]UCB-H PET provides complementary perfusion-like and synaptic information in focal epilepsy and shows spatial correspondence with [18F]FDG PET while offering more spatially confined synaptic signal changes.
引用
- Pakula V, Dorneich JS, Frontzkowski L, et al. Detection of Focal Lesions in Epilepsy with [18F]UCB-H Synaptic Vesicle Protein 2A PET Imaging. J Nucl Med. 2026. PMID: 41927278. doi:10.2967/jnumed.125.271505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。